E. PODOLAK

DOCKET NUMBER (36)
PROPOSED RULE PRM-35-1 (44 FR 26817)

St. Louis University
Medical Center

School of Medicine
1325 S. Grand Blvd., St. Louis, Mo. 63104
314/771-7600

Department of Internal Medicine
Division of Pulmonary Diseases
R. H. Secker-Walker, M.D.
Director

Edith A. Levine, M.D.
Joseph M. Seria, M.D.
Jan Blomefield, R.N., R.R.T.

DOCKETED
USNRC
JUN 29 1979
Office of the Secretary
Docketing & Service
Branch

June 25, 1979

Samuel J. Chilk
Secretary of the Commission
United States Nuclear Regulatory Commission
Washington, D.C. 20555

Attention: Docketing and Service Branch

Dear Mr. Chilk:

I am writing in support of Dr. George V. Taplin's petition for Rule Making dated March 28, 1979 and published in the Federal Register, Vol. 44, No. 89, Monday, May 7, 1979; page 26817.

I would urge the Commission to reconsider and rescend the requirement that physicians must use an approved radiopharmaceutical strictly in accordance with the manufacturer's package insert, as required by the Commission Amendment to its regulation 10 CFR Part 35, published in the Federal Register (44 FR 10358).

As Dr. Taplin points out, this amendment would prevent the use of Technetium 99m DTPA as an aerosol by inhalation for lung imaging. Dr. Taplin and his colleagues have shown that this use of Technetium 99m DTPA provides information to the physician which can prove useful in the diagnosis and management of a variety of pulmonary diseases. In the process, the patient is exposed to lower levels of radiation than are received during the approved uses of Technetium 99m DTPA for kidney or brain scanning.

Sincerely,

Roger H. Secker-Walker, M.D.
Professor of Medicine and Physiology

RSW:jw

acknowledged by card.... a/h 7/2/79

927 315

7909070537